Difference between revisions of "Vortioxetine-dosulepine"
From Psychiatrienet
| Line 6: | Line 6: | ||
* '''Day 7:''' stop administration of vortioxetine. | * '''Day 7:''' stop administration of vortioxetine. | ||
| start = | | start = | ||
| − | * '''Day 8:''' start administration of dosulepine | + | * '''Day 8:''' start administration of dosulepine with 25 mg/day. |
| − | + | {{GoSlow}} | |
| info = | | info = | ||
| − | |||
* {{theorSS}}<ref>[[European Medicines Agency]] | SmPC Brintellix 5 mg. </ref> | * {{theorSS}}<ref>[[European Medicines Agency]] | SmPC Brintellix 5 mg. </ref> | ||
}} | }} | ||
Revision as of 17:03, 11 March 2015
| ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
Switch medication from vortioxetine to dosulepine.[1] [2]
Stop vortioxetine - Day 1: reduce dosage of vortioxetine to 5 mg/day.
- Day 7: stop administration of vortioxetine.
Start dosulepine- Day 8: start administration of dosulepine with 25 mg/day.
- Titrate slowly
More information- Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.[3]
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ European Medicines Agency | SmPC Brintellix 5 mg.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
